Drugs / CNSI-Fe(II)
CNSI-Fe(II)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06048367 | Nov 2022 → Sep 2024 | breast cancer, cervical cancer, colorectal cancer, lung cancer +4 | Sichuan Enray Pharmaceutical Sciences Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNSI-Fe(II) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06048367 ↗ |
| Known as | carbon nanoparticles-Fe(II) complex | “Herein, we report that a carbon nanoparticles-Fe(II) complex (CNSI-Fe) could efficiently load Fe into tumor cells and inhibit tumor growth with low toxicity in H22 tumor-bearing mice.” PMID 32510916 ↗ Jun 2020 |
| Known as | CNSI-Fe | “Herein, we report that a carbon nanoparticles-Fe(II) complex (CNSI-Fe) could efficiently load Fe into tumor cells and inhibit tumor growth with low toxicity in H22 tumor-bearing mice.” PMID 32510916 ↗ Jun 2020 |